| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Steroid Hormones Section, National Institute of Diabetes and Digestive and Kidney Diseases/Laboratory of Molecular and Cellular Biology, National Institutes of Health, Bethesda, Maryland 20892
Address all correspondence and requests for reprints to: Dr. S. Stoney Simons, Jr., Building 8, Room B2A-07, National Institute of Diabetes and Digestive and Kidney Disease/Laboratory of Molecular and Cellular Biology, National Institutes of Health, Bethesda, Maryland 20892. E-mail: steroids{at}helix.nih.gov.
Corepressors and coactivators can modulate the dose-response curve and partial agonist activity of glucocorticoid receptors (GRs) complexed with agonist and antagonist steroids, respectively, in intact cells. We recently reported that GR-antagonist complexes bind to the coactivator TIF2, (transcriptional intermediary factor 2), which is consistent with the whole-cell effects of coactivators being mediated by direct interactions with GR complexes. We now ask whether the whole-cell modulatory activity of corepressors also entails binding to both GR-agonist and -antagonist complexes and whether the association of corepressors and coactivators with GR complexes involves competitive equilibrium reactions. In mammalian two-hybrid assays with two different cell lines and in cell-free pull-down and whole-cell immunoprecipitation assays, the corepressors NCoR (nuclear receptor corepressor) and SMRT (silencing mediator of retinoid and thyroid hormone receptor) associate with agonist and antagonist complexes of GRs. Both N- and C-terminal regions of GR are needed for corepressor binding, which requires the CoRNR box motifs that mediate corepressor binding to other nuclear/steroid receptors. Importantly, whole-cell GR interactions with corepressors are competitively inhibited by excess coactivator and vice versa. However, the regions of the coactivator TIF2 that compete for GR binding to corepressor and coactivator are not the same, implying a molecular difference in GR association with coactivators and corepressors. Finally, when the whole-cell ratio of coactivators to corepressors is altered by selective cofactor binding to exogenous thyroid receptor ß ± thyroid hormone, the GR dose-response-curve and partial agonist activity are appropriately modified. Such modifications are independent of histone acetylation. We conclude that mutually antagonistic equilibrium interactions of corepressors and coactivators modulate the dose-response curve and partial agonist activity of GR complexes in a manner that is responsive to the intracellular ratio of these two classes of cofactors. This modulation provides an attractive mechanism for differential control of gene expression during development, differentiation, homeostasis, and endocrine therapies.
NURSA Molecule Pages Link:
This article has been cited by other articles:
 |
|
 |
|
  J. Yang and M. J Young The mineralocorticoid receptor and its coregulators J. Mol. Endocrinol., August 1, 2009; 43(2): 53 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Newton and N. S. Holden Separating Transrepression and Transactivation: A Distressing Divorce for the Glucocorticoid Receptor? Mol. Pharmacol., October 1, 2007; 72(4): 799 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Li, M. E Andersen, S. Heber, and Q. Zhang Non-monotonic dose-response relationship in steroid hormone receptor-mediated gene expression J. Mol. Endocrinol., May 1, 2007; 38(5): 569 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. He and S. S. Simons Jr. STAMP, a Novel Predicted Factor Assisting TIF2 Actions in Glucocorticoid Receptor-Mediated Induction and Repression Mol. Cell. Biol., February 15, 2007; 27(4): 1467 - 1485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Jiang and S. S Stojilkovic Molecular cloning and characterization of {alpha}1-soluble guanylyl cyclase gene promoter in rat pituitary cells J. Mol. Endocrinol., December 1, 2006; 37(3): 503 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Voss, S. John, and G. L. Hager Single-Cell Analysis of Glucocorticoid Receptor Action Reveals that Stochastic Post-Chromatin Association Mechanisms Regulate Ligand-Specific Transcription Mol. Endocrinol., November 1, 2006; 20(11): 2641 - 2655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wu, H. Kawate, K. Ohnaka, H. Nawata, and R. Takayanagi Nuclear Compartmentalization of N-CoR and Its Interactions with Steroid Receptors. Mol. Cell. Biol., September 1, 2006; 26(17): 6633 - 6655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Duret, M. Daujat-Chavanieu, J.-M. Pascussi, L. Pichard-Garcia, P. Balaguer, J.-M. Fabre, M.-J. Vilarem, P. Maurel, and S. Gerbal-Chaloin Ketoconazole and Miconazole Are Antagonists of the Human Glucocorticoid Receptor: Consequences on the Expression and Function of the Constitutive Androstane Receptor and the Pregnane X Receptor Mol. Pharmacol., July 1, 2006; 70(1): 329 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Rosenfeld, V. V. Lunyak, and C. K. Glass Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response Genes & Dev., June 1, 2006; 20(11): 1405 - 1428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Li, J. H. Heaton, and T. D. Gelehrter Role of Steroid Receptor Coactivators in Glucocorticoid and Transforming Growth Factor {beta} Regulation of Plasminogen Activator Inhibitor Gene Expression Mol. Endocrinol., May 1, 2006; 20(5): 1025 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Albers, B. Blume, T. Schlueter, M. B. Wright, I. Kober, C. Kremoser, U. Deuschle, and M. Koegl A Novel Principle for Partial Agonism of Liver X Receptor Ligands: COMPETITIVE RECRUITMENT OF ACTIVATORS AND REPRESSORS J. Biol. Chem., February 24, 2006; 281(8): 4920 - 4930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ichijo, A. Voutetakis, A. P. Cotrim, N. Bhattachryya, M. Fujii, G. P. Chrousos, and T. Kino The Smad6-Histone Deacetylase 3 Complex Silences the Transcriptional Activity of the Glucocorticoid Receptor: POTENTIAL CLINICAL IMPLICATIONS J. Biol. Chem., December 23, 2005; 280(51): 42067 - 42077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wang and S. S. Simons Jr. Corepressor Binding to Progesterone and Glucocorticoid Receptors Involves the Activation Function-1 Domain and Is Inhibited by Molybdate Mol. Endocrinol., June 1, 2005; 19(6): 1483 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yu, K. Markan, K. A. Temple, D. Deplewski, M. J. Brady, and R. N. Cohen The Nuclear Receptor Corepressors NCoR and SMRT Decrease Peroxisome Proliferator-activated Receptor {gamma} Transcriptional Activity and Repress 3T3-L1 Adipogenesis J. Biol. Chem., April 8, 2005; 280(14): 13600 - 13605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Hodgson, I. Astapova, S. Cheng, L. J. Lee, M. C. Verhoeven, E. Choi, S. P. Balk, and A. N. Hollenberg The Androgen Receptor Recruits Nuclear Receptor CoRepressor (N-CoR) in the Presence of Mifepristone via Its N and C Termini Revealing a Novel Molecular Mechanism for Androgen Receptor Antagonists J. Biol. Chem., February 25, 2005; 280(8): 6511 - 6519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cho, B. L. Kagan, J. A. Blackford Jr., D. Szapary, and S. S. Simons Jr. Glucocorticoid Receptor Ligand Binding Domain Is Sufficient for the Modulation of Glucocorticoid Induction Properties by Homologous Receptors, Coactivator Transcription Intermediary Factor 2, and Ubc9 Mol. Endocrinol., February 1, 2005; 19(2): 290 - 311. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
